阜博集團(03738.HK)擬配售2150萬股籌資6.32億港元 用於科技投資及全球擴展
格隆匯5月21日丨阜博集團(03738.HK)公吿,於2021年5月21日,公司與獨家配售代理訂立配售協議,公司擬按認購價每股配售股份30.30港元配售合共2150萬股,相當於公司現有已發行股本總額約4.66%;及經配發擴大後已發行股本總額約4.45%。
預計配售事項所得款項淨額合共約為6.32億港元。公司擬將所得款項淨額用於科技投資、集團客户的全球擴展及一般企業用途。
董事已考慮多種集資選擇。經審閲配售事項條款及條件後,董事會認為,透過配售事項籌集股本資金乃符合公司利益,可擴大其股東基礎、增強資本基礎及提升集團財務狀況及淨資產基礎,以促進其長期發展及增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.